Stockholm - Delayed Quote ? SEK Getinge AB (publ) (GETI-B.ST) Follow Compare 198.50 -2.40 (-1.19%) At close: October 25 at 5:29 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Getinge AB (GNGBF) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges Getinge AB (GNGBF) reports strong order intake and strategic acquisitions, while addressing supply chain and margin pressures. GuruFocus.com ? 7 days ago GNGBY Getinge completes Paragonix Technologies acquisition Paragonix is engaged in developing, manufacturing, and providing services in the organ transplant industry. Medical Device Network ? last month GNGBY Getinge completes the acquisition of Paragonix Technologies On August 22, 2024, Getinge announced that it had entered into an agreement to acquire Paragonix Technologies, Inc., a leading U.S. company in organ transport products and services, for a total purchase price estimated at USD 477 million, including upfront and currently estimated earn-outs. PR Newswire ? last month GNGBF GNGBY Getinge to buy Paragonix organ-preserving tech for up to $477M Getinge will pay $253 million in cash at closing, with additional payments expected to be made between 2024 and 2026 if certain milestones are met. MedTech Dive ? 2 months ago GNGBY FDA issues 510(k) clearance for Getinge’s Talis +ACG software The software suite includes Talis-Anesthesia, Talis-Perfusion, Talis-RemoteView, and Talis-ECMO applications. Medical Device Network ? 4 months ago GNGBY Getinge to limit US sales of heart devices after FDA safety warning CEO Mattias Perjos said?the action will have “some negative financial impact,” but the total effect will depend on customers'?response. MedTech Dive ? 5 months ago GNGBY FDA tells providers to stop using Getinge heart devices After months of safety concerns, the FDA said Getinge?has?yet to “sufficiently” address the problems and risks. MedTech Dive ? 5 months ago GNGBY FDA issues warning on Getinge device amid quality concerns Following a series of voluntary recalls, the FDA has urged healthcare providers to avoid Getinge’s intra-aortic balloon pumps over safety concerns. Medical Device Network ? 5 months ago GNGBY UPDATE 2-US FDA advises healthcare facilities to switch from Getinge's heart devices The U.S Food and Drug Administration (FDA) on Wednesday advised healthcare facilities to move away from using Getinge's heart devices in patients as they faced safety and quality concerns despite a string of recalls. Getinge did not immediately respond to a Reuters request for comment. The FDA suggests providers to move away from the use of Getinge's Cardiosave Hybrid and Rescue Intra-Aortic Balloon Pump (IABP) devices and its Cardiohelp system and HLS Sets. Reuters ? 5 months ago GNGBY Getinge AB's Dividend Analysis Getinge AB (GNGBY) recently announced a dividend of $0.42 per share, payable on 2024-05-14, with the ex-dividend date set for 2024-04-23. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Getinge AB's dividend performance and assess its sustainability. GuruFocus.com ? 6 months ago GNGBY Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return GETI-B.ST OMX Stockholm 30 Index YTD -9.79% +8.09% 1-Year +4.49% +24.98% 3-Year -49.03% +10.36%
